Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Neurology

How Fast Does CMT1A Progress in Adults? | Inciteful Med

At a Glance

Charcot-Marie-Tooth disease type 1A (CMT1A) progresses very slowly over decades. Sudden declines are rare, and the vast majority of adults with CMT1A continue to walk independently throughout their lives without needing a wheelchair. Assistive devices like AFO braces help maintain mobility.

In this answer

5 sections

01

The Typical Course of the Disease

02

Measuring Your Progression

03

Managing Your Mobility and Independence

04

Factors That Can Affect Your Symptoms

05

Planning for the Future

If you have been diagnosed with Charcot-Marie-Tooth disease type 1A (CMT1A), one of your biggest concerns is likely how quickly your symptoms will worsen and whether you will eventually lose your independence. The most reassuring fact about CMT1A is that it typically progresses very slowly over decades [1][2]. While it is a lifelong condition that causes gradual changes in muscle strength and sensation, sudden or drastic declines are rare [3][4]. Most importantly, the vast majority of people living with CMT1A remain ambulatory—meaning they can continue to walk independently—and do not require the use of a full-time wheelchair [5][6].

The Typical Course of the Disease

Because CMT affects the peripheral nerves (those furthest from the center of your body), weakness typically begins in the feet and lower legs [7][6]. This can lead to gait abnormalities, frequent tripping, and difficulty balancing [8][9]. As CMT1A progresses later in life, weakness and sensory loss often advance to the hands and forearms [7][6]. This can cause difficulties with fine motor skills, such as buttoning shirts, writing, or opening jars, which is just as important to monitor as your walking ability.

Measuring Your Progression

Neurologists often use specialized scoring systems, like the Charcot-Marie-Tooth Neuropathy Score (CMTNS), to track how the disease changes over time [10]. This assessment measures your strength, reflexes, and sensation to give a clinical severity score on a scale from 0 to 36.

Longitudinal studies observing adult patients have shown that CMTNS scores increase very slowly [3]. On average, clinical scores change by less than 1 point per year [4][11]. Because this rate of decline is so gradual, changes in your day-to-day abilities usually happen over a span of many years rather than months [12][6]. Notably, research indicates that the rate of progression does not suddenly accelerate as you get older; the slow pace remains relatively consistent whether you are under or over age 50 [4].

Managing Your Mobility and Independence

To maintain mobility and independence as symptoms gradually evolve, many patients successfully utilize assistive devices. The use of orthotics, such as Ankle-Foot Orthoses (AFOs) (custom braces that support the ankle and lift the foot), and walking aids like canes or walking sticks is common and highly effective [13][6]. By managing foot drop and improving stability, these tools allow patients to stay active and on their feet.

Factors That Can Affect Your Symptoms

While CMT1A itself is slowly progressive, certain factors can make your symptoms feel worse or progress differently:

  • Neurotoxic Medications: Certain drugs, most notably the chemotherapy agent vincristine, can cause rapid, severe, and sometimes irreversible neurological decline in CMT patients [14][15]. It is essential to consult with a pharmacist or neurologist and review evidence-based warning lists before starting any new medications [16][17].
  • Comorbidities: Having other health conditions, particularly diabetes mellitus, is associated with more severe nerve damage and clinical symptoms in CMT1A patients [18][19]. Managing blood sugar and overall health is critical.
  • Physical Activity: Maintaining a safe, doctor-approved exercise routine—such as low-impact aerobic exercises like swimming or cycling—can help maximize the function of unaffected muscles and improve balance, even if it cannot reverse nerve damage [9].
  • Weight Management: Carrying excess body weight places additional physical strain on weakened foot and leg muscles, making mobility more challenging.
  • Foot Care: Because CMT1A causes sensory loss and structural foot changes, patients are at a higher risk for undetected blisters or ulcers from orthotics or shoes, making daily foot inspections important [20].

Planning for the Future

While acknowledging that your physical abilities will slowly change, you can plan for a long, independent life. Regular visits to a neuromuscular specialist or a multidisciplinary CMT clinic will ensure that your strength and mobility are monitored [5][21]. They can also help introduce physical therapy, occupational therapy (to assist with daily living tasks and hand function), or orthotics at the right time to keep you moving safely and comfortably.

Common questions in this guide

Will I eventually need a wheelchair with CMT1A?
The vast majority of people with CMT1A remain able to walk independently throughout their lives. It is rare to require full-time wheelchair use, though many patients benefit from using supportive braces or walking canes for stability.
How does a doctor track if my CMT1A is getting worse?
Neurologists often use the Charcot-Marie-Tooth Neuropathy Score (CMTNS) to track your progression. This clinical assessment measures your strength, reflexes, and sensation over time, with scores typically changing by less than one point per year.
Can medications make my CMT1A symptoms progress faster?
Yes, certain neurotoxic medications, especially the chemotherapy drug vincristine, can cause rapid and sometimes irreversible nerve damage. You should always review new prescriptions with your pharmacist or neurologist before taking them.
Will CMT1A eventually affect my hands and arms?
While weakness typically begins in the feet and lower legs, it often advances to the hands and forearms later in life. This can cause gradual difficulty with fine motor skills, such as writing, buttoning shirts, or opening jars.
How can diabetes affect my CMT1A progression?
Having diabetes can accelerate nerve damage and worsen the clinical symptoms of CMT1A. Carefully managing your blood sugar and overall health is an important step in protecting your peripheral nerves.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my current CMTNS score, how often should we be formally measuring my progression to ensure we aren't missing any subtle changes?
  2. 2.At what point in my disease progression should I consider trying an Ankle-Foot Orthosis (AFO) to protect my mobility?
  3. 3.Are there specific low-impact exercises or physical therapy routines you recommend to maximize the function of my unaffected muscles?
  4. 4.What specific neurotoxic medications should I completely avoid, and do you have a comprehensive list I can share with my pharmacist?
  5. 5.When should I consider seeing an occupational therapist to help maintain fine motor skills in my hands and fingers?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can You Get CMT1A Without a Family History?Carbon Fiber vs Plastic AFOs for CMT: Which is Better?How Does Diabetes Affect Charcot-Marie-Tooth Type 1A?How to Prevent Passing CMT1A to Children | Inciteful MedWhat Are the Best Medications for CMT1A Nerve Pain?What Are the Best Physical Therapy Exercises for CMT1A?What Are the Early Symptoms of CMT1A in Children?What is the Difference Between CIDP and CMT1A?What is the Life Expectancy for Charcot-Marie-Tooth 1A?What Medications Are Neurotoxic for CMT?What to Ask Your Neurologist About CMT1A at Your Check-UpWhy Are My CMT1A Symptoms Worse Than My Parent's?

References

References (21)
  1. 1

    Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease.

    Piscosquito G, Reilly MM, Schenone A, et al.

    European journal of neurology 2015; (22(12)):1556-63 doi:10.1111/ene.12783.

    PMID: 26227902
  2. 2

    Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease.

    Millere E, Rots D, Simrén J, et al.

    European journal of neurology 2021; (28(3)):974-981 doi:10.1111/ene.14689.

    PMID: 33340200
  3. 3

    A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores.

    Fridman V, Sillau S, Acsadi G, et al.

    Neurology 2020; (94(9)):e884-e896 doi:10.1212/WNL.0000000000009035.

    PMID: 32047073
  4. 4

    Rate of Changes in CMT Neuropathy and Examination Scores in Japanese Adult CMT1A Patients.

    Kitani-Morii F, Noto YI, Tsuji Y, et al.

    Frontiers in neurology 2020; (11()):626 doi:10.3389/fneur.2020.00626.

    PMID: 32765395
  5. 5

    A study concept of expeditious clinical enrollment for genetic modifier studies in Charcot-Marie-Tooth neuropathy 1A.

    Xu IRL, Danzi MC, Ruiz A, et al.

    Journal of the peripheral nervous system : JPNS 2024; (29(2)):202-212 doi:10.1111/jns.12621.

    PMID: 38581130
  6. 6

    Patient-Reported Symptom Burden of Charcot-Marie-Tooth Disease Type 1A: Findings From an Observational Digital Lifestyle Study.

    Thomas FP, Saporta MA, Attarian S, et al.

    Journal of clinical neuromuscular disease 2022; (24(1)):7-17 doi:10.1097/CND.0000000000000426.

    PMID: 36005469
  7. 7

    Differentiation of Human Tonsil-Derived Mesenchymal Stem Cells into Schwann-Like Cells Improves Neuromuscular Function in a Mouse Model of Charcot-Marie-Tooth Disease Type 1A.

    Park S, Jung N, Myung S, et al.

    International journal of molecular sciences 2018; (19(8)) doi:10.3390/ijms19082393.

    PMID: 30110925
  8. 8

    Deterioration in gait and functional ambulation in children and adolescents with Charcot-Marie-Tooth disease over 12 months.

    Kennedy R, Carroll K, Paterson KL, et al.

    Neuromuscular disorders : NMD 2017; (27(7)):658-666 doi:10.1016/j.nmd.2017.04.005.

    PMID: 28495045
  9. 9

    Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure.

    Mandarakas MR, Eichinger KJ, Bray P, et al.

    Neurology 2024; (102(3)):e207963 doi:10.1212/WNL.0000000000207963.

    PMID: 38237108
  10. 10

    Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.

    Gess B, Baets J, De Jonghe P, et al.

    The Cochrane database of systematic reviews 2015; CD011952 doi:10.1002/14651858.CD011952.

    PMID: 26662471
  11. 11

    High-density surface electromyography to assess motor unit firing rate in Charcot-Marie-Tooth disease type 1A patients.

    Noto YI, Watanabe K, Holobar A, et al.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2021; (132(3)):812-818 doi:10.1016/j.clinph.2020.11.040.

    PMID: 33483296
  12. 12

    Walking Speed Is Correlated With the Isokinetic Muscular Strength of the Knee in Patients With Charcot-Marie-Tooth Type 1A.

    Reynaud V, Morel C, Givron P, et al.

    American journal of physical medicine & rehabilitation 2019; (98(5)):422-425 doi:10.1097/PHM.0000000000001084.

    PMID: 30365400
  13. 13

    Intraepidermal nerve fibre density as biomarker in Charcot-Marie-Tooth disease type 1A.

    Hartmannsberger B, Doppler K, Stauber J, et al.

    Brain communications 2020; (2(1)):fcaa012 doi:10.1093/braincomms/fcaa012.

    PMID: 32954280
  14. 14

    Pain in Charcot-Marie-Tooth disease: an update.

    Azevedo H, Pupe C, Pereira R, Nascimento OJM

    Arquivos de neuro-psiquiatria 2018; (76(4)):273-276 doi:10.1590/0004-282x20180021.

    PMID: 29742248
  15. 15

    A recurrent MORC2 mutation causes Charcot-Marie-Tooth disease type 2Z.

    Vujovic D, Cornblath DR, Scherer SS

    Journal of the peripheral nervous system : JPNS 2021; (26(2)):184-186 doi:10.1111/jns.12443.

    PMID: 33844363
  16. 16

    Toxic medications in Charcot-Marie-Tooth patients: A systematic review.

    Cavaletti G, Forsey K, Alberti P

    Journal of the peripheral nervous system : JPNS 2023; (28(3)):295-307 doi:10.1111/jns.12566.

    PMID: 37249082
  17. 17

    Understanding medication safety and Charcot-Marie-Tooth disease: a patient perspective.

    Socha Hernandez AV, Deeks LS, Shield AJ

    International journal of clinical pharmacy 2020; (42(6)):1507-1514 doi:10.1007/s11096-020-01123-z.

    PMID: 32804316
  18. 18

    Coexistence of Charcot Marie Tooth disease type 1A and diabetes in Taiwan: A clinicopathological study.

    Chao HC, Chou CT, Lee YC, Lin KP

    Journal of the neurological sciences 2015; (358(1-2)):213-20.

    PMID: 26349404
  19. 19

    High glucose level as a modifier factor in CMT1A patients.

    Secchin JB, Leal RCC, Lourenço CM, et al.

    Journal of the peripheral nervous system : JPNS 2020; (25(2)):132-137 doi:10.1111/jns.12379.

    PMID: 32347995
  20. 20

    Charcot-Marie-Tooth Disease and Other Hereditary Neuropathies.

    Klein CJ

    Continuum (Minneapolis, Minn.) 2020; (26(5)):1224-1256 doi:10.1212/CON.0000000000000927.

    PMID: 33003000
  21. 21

    Reliability of the Charcot-Marie-Tooth functional outcome measure.

    Bray P, Cornett KMD, Estilow T, et al.

    Journal of the peripheral nervous system : JPNS 2020; (25(3)):288-291 doi:10.1111/jns.12406.

    PMID: 32844461

This information about CMT1A progression is for educational purposes only. Always consult a neuromuscular specialist for personalized guidance on managing your symptoms and monitoring your disease.

Get notified when new evidence is published on Charcot-Marie-Tooth disease type 1A.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.